🇺🇸 FDA
Pipeline program

Teduglutide (ALX-0600)

CL0600-009

Phase 2 small_molecule completed

Quick answer

Teduglutide (ALX-0600) for Crohn's Disease is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Crohn's Disease
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials